UNITED STATES OF AMERICA  
Before the  
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934  
Release No. 91774 / May 5, 2021

ADMINISTRATIVE PROCEEDING  
File No. 3-19983

In the Matter of  
Clontech Laboratories, Inc. n/k/a Takara Bio USA, Inc.,  
Respondent.

ORDER MAKING FINDINGS AND REVOKING REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(j) OF THE SECURITIES EXCHANGE ACT OF 1934

I.

The Securities and Exchange Commission (“Commission”) deems it necessary and appropriate for the protection of investors to accept the Offer of Settlement submitted by Clontech Laboratories, Inc. n/k/a Takara Bio USA, Inc. (“Clontech” or “Respondent”) pursuant to Rule 240(a) of the Rules of Practice of the Commission, 17 C.F.R. § 201.240(a), for the purpose of settlement of these proceedings initiated against Respondent on September 10, 2020, pursuant to Section 12(j) of the Securities Exchange Act of 1934 (“Exchange Act”).

II.

Solely for the purpose of these proceedings and any other proceedings brought by or on behalf of the Commission, or to which the Commission is a party, and without admitting or denying the findings herein, except as to the Commission’s jurisdiction over it and the subject matter of these proceedings, which are admitted, Respondent consents to the entry of this Order Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the Securities Exchange Act of 1934 (“Order”), as set forth below.
On the basis of this Order and Respondent’s Offer, the Commission finds that:\n
1. Clontech Laboratories, Inc. n/k/a Takara Bio USA, Inc. (CIK No. 0000816281) is a delinquent Delaware corporation located in Mountain View, California with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). As of August 14, 2020, the common stock of Clontech was not publicly quoted or traded.

2. Clontech has failed to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 thereunder because it has not filed any periodic reports with the Commission since it filed a Form 8-A12G on March 3, 1999.

In view of the foregoing, the Commission deems it necessary and appropriate for the protection of investors to impose the sanction specified in Respondent’s Offer.

Accordingly, it is hereby ORDERED that:

Pursuant to Section 12(j) of the Exchange Act, the registration of each class of Respondent’s securities registered pursuant to Exchange Act Section 12 be, and hereby is, revoked. The revocation is effective as of May 6, 2021.\n
For the Commission, by its Secretary, pursuant to delegated authority.

Vanessa A. Countryman  
Secretary

\n
---

1The findings herein are made pursuant to Respondent’s Offer of Settlement and are not binding on any other person or entity in this or any other proceeding.

2This Order applies to all classes of Respondent’s securities registered pursuant to Section 12 of the Exchange Act, whether or not such securities are specifically identified by ticker symbol or otherwise in this Order.